Open AccessEfficacy and safety of Shufeng Jiedu capsule for coronavirus disease 2019 (COVID-19)
Author(s) -
Runmin Li,
Ying Li,
Bingchen Li,
Hao Sun,
Xinyu Liu,
Xin Ge,
Yuanxiang Liu,
Jiguo Yang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021615
Subject(s) - medicine , inclusion and exclusion criteria , covid-19 , cochrane library , medline , randomized controlled trial , meta analysis , adverse effect , intensive care medicine , disease , medical physics , alternative medicine , pathology , infectious disease (medical specialty) , outbreak , political science , law
Background: From the end of 2019 to the present, coronavirus disease 2019 (COVID-19) has put considerable pressure on the worlds medical system and caused significant mortality and economic losses around the world. In China, the Shufeng Jiedu capsule has been widely used in the treatment of COVID-19, but there is still a lack of evidence-based medical evaluation. Methods: According to the retrieval strategies, randomized controlled trials (RCTs) on the Shufeng Jiedu capsule for COVID-19 were obtained from CNKI, WanFang, VIP, PubMed, Embase and Cochrane Library, regardless of publication date, or language. Studies were screened based on inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to evaluate the quality of the studies. The meta-analysis was performed using RevMan 5.3 and STATA 14.2 software. Ultimately, the evidentiary grade for the results will be evaluated. Results: This study will evaluate the efficacy and safety of the Shufeng Jiedu capsule in the treatment of COVID-19 and provide a more reasonable choice of medication in clinical practice. Conclusion: Our findings will provide references for future clinical decision and guidance development. Registration: INPLASY registration number: INPLASY202070024.